Following two (2) years of sluggish revenue performance, GlaxoSmithKline Consumer Plc (GLAXOSMITH) ended 2022FY with double digit topline expansion, anchored on the recovery of its pharmaceutical segment. Revenue from the pharmaceutical segment (c.66% of revenue surged 10.50% YoY to NGN16.75bn (vs NGN15.16bn in 2021FY), anchored on higher prices of prescription medicine as well as higher sales volume in the segment.
You May Also Like
Earnings Update- NASCON | 2021FY
- March 8, 2022
NASCON Allied Industries Plc (NASCON) reported a 18.81%YoY topline expansion in its 2021FY financial period. The firm’s topline…
Earnings Update | GUARANTY | Q1:2020
- April 29, 2020
Guaranty Trust Bank Plc (GUARANTY)’s Q1:2020 performance revealed a stronger than expected growth in gross earnings (2.30% YoY),…
Earnings Update | GUARANTY | H1:2020
- September 13, 2020
In the first half of the year, Guaranty Trust Bank Plc (GUARANTY)’s gross earnings were pressured by a…
Earnings Update | ARDOVA | Q1:2020
- June 29, 2020
ARDOVA’s topline expanded to NGN52.05bn in Q1:2020 (+22.31% YoY). The growth was off the back of a 24.61%…
Earnings Update – ZENITHBANK 2022FY Impairment Charge on Ghana’s Sovereign Bonds Drags Profitability
- April 4, 2023
For the first time since 2017, Zenith Bank Plc. (ZENITHBANK) recorded double-digit growth in gross earnings. Remarkably, the…
Earnings Update | NASCON | Q1:2020
- April 30, 2020
NASCON, in its Q1:2020 financial scorecard reported a marginal uptick (+0.83%) in revenue to NGN6.88bn (vs. NGN6.82bn in…